Table 1. Demographic and clinical characteristic of study sample.
| Variables | Values |
|---|---|
| Sex | |
| Male | 13 (76.5) |
| Female | 4 (23.5) |
| Race | |
| Non-Hispanic/White | 14 (82.4) |
| Hispanic | 1 (5.9) |
| American Indian | 1 (5.9) |
| Black | 1 (5.9) |
| Comorbidities | |
| None | 11 (64.7) |
| Chronic kidney disease | 2 (11.8) |
| End stage renal disease | 2 (11.8) |
| Cirrhosis | 0 (0.0) |
| End stage renal disease and cirrhosis | 1 (5.9) |
| Unknown | 1 (5.9) |
| Etiology of pleural effusion | |
| Complicated parapneumonic effusion/empyema | 16 (94.1) |
| Multiloculated complex malignant effusion | 1 (5.9) |
| Past systemic bleeding history | |
| Yes | 0 |
| No | 17 (100.0) |
| Timing of lab draw during tPA and DNase treatment | |
| 1st treatment | 9 (52.9) |
| 2nd treatment | 4 (23.5) |
| 3rd treatment | 3 (17.7) |
| 4th treatment | 1 (5.9) |
| Positive pleural blood cultures | |
| Yes | 10 (58.8) |
| No | 7 (41.2) |
| Age (years) | 67 [62, 71] |
| BMI (kg/m2) | 26.1 [23.8, 34.7] |
| Pleural fluid pH | 7.1 [6.9, 7.3] |
| Time from tPA/DNase dose to post-blood draw (minutes) | 75 [64, 98] |
Data are presented as n (%) or median [IQR]. tPA, tissue plasminogen activator; DNase, dornase alfa; BMI, body mass index; IQR, interquartile range.